Exploration of Targeted Anti-tumor Therapy

Open Access Review

Engineered phosphorus dendrimers as powerful non-viral nanoplatforms for gene delivery: a great hope for the future of cancer therapeutics

Serge Mignani ... Jean-Pierre Majoral

Published: February 25, 2022 Explor Target Antitumor Ther. 2022;3:50–61

DOI: https://doi.org/10.37349/etat.2022.00071

This article belongs to the special issue Gene Delivery Approach to Fight Cancer

Full Text PDF

4890 54 6

Open Access Review

Non-invasive detection of epithelial mesenchymal transition phenotype and metastatic dissemination of lung cancer by liquid biopsy

Viviana De Rosa ... Francesca Iommelli

Published: February 28, 2021 Explor Target Antitumor Ther. 2021;2:36–47

DOI: https://doi.org/10.37349/etat.2021.00032

This article belongs to the special issue Liquid Biopsy in Thoracic Cancer

Full Text PDF

4857 41 1

Open Access Perspective

Anticancer action of plant products: changing stereotyped attitudes

Katrin Sak

Published: August 15, 2022 Explor Target Antitumor Ther. 2022;3:423–427

DOI: https://doi.org/10.37349/etat.2022.00092

This article belongs to the special issue Plant Extracts as an Infinite Resource for New Anticancer Agents

Full Text PDF

4840 63 10

Open Access Review

B-cell lymphoma 2 family members and sarcomas: a promising target in a heterogeneous disease

Rui Caetano Oliveira ... José Casanova

Published: August 24, 2023 Explor Target Antitumor Ther. 2023;4:583–599

DOI: https://doi.org/10.37349/etat.2023.00154

This article belongs to the special issue The Role of Bcl-2 Family Proteins in Cancer Progression and Their Relevance to Cancer Therapy

Full Text PDF

4824 34 1

Open Access Review

Overview on biomarkers for immune oncology drugs

Evgeny N. Imyanitov ... Natalia V. Mitiushkina

Published: March 17, 2025 Explor Target Antitumor Ther. 2025;6:1002298

DOI: https://doi.org/10.37349/etat.2025.1002298

This article belongs to the special issue Immune Checkpoint Therapy and Biomarkers in Cancer

Full Text PDF

4811 33 5

Open Access Review

Role of artificial intelligence in oncologic emergencies: a narrative review

Salvatore Claudio Fanni ... Emanuele Neri

Published: April 28, 2023 Explor Target Antitumor Ther. 2023;4:344–354

DOI: https://doi.org/10.37349/etat.2023.00138

This article belongs to the special issue Artificial Intelligence for Precision Oncology

Full Text PDF

4810 55 8

Open Access Case Report

Complete response to third-line treatment with trifluridine/tipiracil (TAS-102) in stage IV colon adenocarcinoma

Celia Lara-Morga ... Luis Cabezón-Gutiérrez

Published: April 27, 2023 Explor Target Antitumor Ther. 2023;4:307–315

DOI: https://doi.org/10.37349/etat.2023.00136

This article belongs to the special issue Biomarkers for Personalized and Precise Cancer Diagnosis and Treatment

Full Text PDF

4809 32 1

Open Access Original Article

Collateral-resistance to estrogen and HER-activated growth is associated with modified AKT, ERα, and cell-cycle signaling in a breast cancer model

Kate M. Moore ... Simon P. Langdon

Published: February 28, 2022 Explor Target Antitumor Ther. 2022;3:97–116

DOI: https://doi.org/10.37349/etat.2022.00074

This article belongs to the special issue Endocrine Resistant Breast Cancer

Full Text PDF

4803 73 1

Open Access Original Article

Racial disparities in hepatocellular carcinoma: a TCGA-based gene expression study of Caucasian and Asian populations

Muhammad Rezki Rasyak ... Caecilia Sukowati

Published: November 02, 2025 Explor Target Antitumor Ther. 2025;6:1002344

DOI: https://doi.org/10.37349/etat.2025.1002344

Full Text PDF

4787 29 1

Open Access Original Article

Diagnostic utility of prostate health index density prior to MRI-ultrasound fusion targeted biopsy

Benjamin H. Press ... Preston C. Sprenkle

Published: September 13, 2024 Explor Target Antitumor Ther. 2024;5:1168–1176

DOI: https://doi.org/10.37349/etat.2024.00269

Full Text PDF

4775 33 1

Open Access Review

An overview of the feasibility of nanomedicine in pancreatic cancer theranostics

Kyriakos Kokkinogoulis ... Mersini Makropoulou

Published: June 18, 2025 Explor Target Antitumor Ther. 2025;6:1002326

DOI: https://doi.org/10.37349/etat.2025.1002326

This article belongs to the special issue Use of Different Radiation Treatment Modalities in Cancer Therapy: The Role of Inflammation and Immune Response

Full Text PDF

4719 28 3

Open Access Review

Interface between obesity with dysfunctional metabolism and inflammation, and the triple-negative breast cancer in African American women

Katarzyna Rygiel

Published: December 31, 2021 Explor Target Antitumor Ther. 2021;2:602–616

DOI: https://doi.org/10.37349/etat.2021.00066

This article belongs to the special issue Endocrine Resistant Breast Cancer

Full Text PDF

4701 62 1

Open Access Original Article

Allosteric cross-talk between the hydrophobic cleft and the BH4 domain of Bcl-2 in control of inositol 1,4,5-trisphosphate receptor activity

George Shapovalov ... Natalia Prevarskaya

Published: June 28, 2022 Explor Target Antitumor Ther. 2022;3:375–391

DOI: https://doi.org/10.37349/etat.2022.00088

This article belongs to the special issue The Role of Bcl-2 Family Proteins in Cancer Progression and Their Relevance to Cancer Therapy

Full Text PDF

4671 66 3

Open Access Original Article

Identification of lysyl oxidase as an adipocyte-secreted mediator that promotes a partial mesenchymal-to-epithelial transition in MDA-MB-231 cells

Cassidy M. Van Stiphout ... Alicia M. Viloria-Petit

Published: January 16, 2024 Explor Target Antitumor Ther. 2024;5:1–19

DOI: https://doi.org/10.37349/etat.2024.00201

This article belongs to the special issue Innovative Strategies to Target Triple-negative Breast Cancer

Full Text PDF

4633 33 3

Open Access Original Article

Acryl-3,5-bis(2,4-difluorobenzylidene)-4-piperidone targeting cellular JUN proto-oncogene, AP-1 transcription factor subunit inhibits head and neck squamous cell carcinoma progression

Levi Arnold ... Sufi Mary Thomas

Published: October 31, 2023 Explor Target Antitumor Ther. 2023;4:1104–1121

DOI: https://doi.org/10.37349/etat.2023.00184

This article belongs to the special issue Therapeutic Targeting of the Tumor Microenvironment

Full Text PDF

4631 93 3

Open Access Review

Next-generation nanocarriers for precision antitumor therapy: from passive targeting to intelligent response

Dilpreet Singh, Akshay Kumar

Published: December 28, 2025 Explor Target Antitumor Ther. 2025;6:1002355

DOI: https://doi.org/10.37349/etat.2025.1002355

Full Text PDF

4628 73 18

Open Access Mini Review

The evolving landscape of first-line and subsequent therapies in EGFR-mutated NSCLC: efficacy, resistance, and tolerability

Carminia Maria Della Corte ... Floriana Morgillo

Published: April 27, 2026 Explor Target Antitumor Ther. 2026;7:1002370

DOI: https://doi.org/10.37349/etat.2026.1002370

Full Text PDF

4593 66 0

Open Access Case Report

Immune checkpoint inhibitor-induced cholangitis—a three-case series

Simon Gray ... Anna Olsson-Brown

Published: July 19, 2024 Explor Target Antitumor Ther. 2024;5:818–825

DOI: https://doi.org/10.37349/etat.2024.00250

Full Text PDF

4583 22 3

Open Access Original Article

Continuous enzyme activity assay for high-throughput classification of histone deacetylase 8 inhibitors

Markus Schweipert ... Franz-Josef Meyer-Almes

Published: June 30, 2023 Explor Target Antitumor Ther. 2023;4:447–459

DOI: https://doi.org/10.37349/etat.2023.00144

Full Text PDF

4535 48 7

Open Access Case Report

Upper tract urothelial cancer (UTUC) genomic profiling and correlation regarding benefit of platinum-based chemotherapy

Min Woo Hwang ... Jeanny B. Aragon-Ching

Published: October 17, 2024 Explor Target Antitumor Ther. 2024;5:1261–1270

DOI: https://doi.org/10.37349/etat.2024.00274

This article belongs to the special issue Emerging Molecular Targets and Therapies of Genitourinary Tumors

Full Text PDF

4532 31 3